Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?

Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald. Opus Point’s equity portfolio is worth $178.32 million as of the end of September, up from $103.54 million at the end of June. The fund invests mainly in healthcare stocks, which amass around 73% of its equity portfolio.

Based on our methodology, the fund had a return of 12.56% last quarter. In our calculations, we only used the fund’s 35 long positions in companies valued at least $1.0 billion. In this article, we’ll discuss three stocks that rank among Opus Point’s top picks, Bristol Myers Squibb Co. (NYSE:BMY),  Alkermes Plc (NASDAQ:ALKS), and AstraZeneca plc (ADR) (NYSE:AZN), as well as one stock in which the fund closed its stake in the third quarter.

mri, doctor, physicians, display, treatment, idea, medic, experiment, pharmaceutical, patient, future, interface, laboratory, multimedia, intelligence, male, digital, scan,


In Bristol Myers Squibb Co. (NYSE:BMY), Opus Point Partners Management inched up its stake by 5% to 75,686 shares worth $4.08 million during the third quarter. The fund increased its exposure to the company as the stock lost 26.7% between July and September. At the end of June, 61 funds followed by us, up by 3% over the quarter. The largest stake in Bristol Myers Squibb Co. (NYSE:BMY) was held by Adage Capital Management, which reported holding $396.8 million worth of stock as of the end of June. It was followed by OrbiMed Advisors with a $371.8 million position. Other investors bullish on the company included Citadel Investment Group, Columbus Circle Investors, and Partner Fund Management.


Follow Bristol Myers Squibb Co (NYSE:BMY)
Trade (NYSE:BMY) Now!

Opus Point Partners Management reported ownership of 81,677 shares of Alkermes Plc (NASDAQ:ALKS) valued at $3.84 million as of the end of September. During the third quarter, the stock appreciated by 8.8%. There were 25 funds from our database long Alkermes Plc (NASDAQ:ALKS) at the end of June, down by one fund over the quarter. Among these funds, Woodford Investment Management, led by Neil Woodford, held the biggest position in Alkermes Plc (NASDAQ:ALKS), which was worth $325.7 million at the end of June. It was followed by D. E. Shaw, with a $60.6 million position. Other hedge funds and institutional investors that hold long positions consist of Stephen DuBois’s Camber Capital Management, Ken Griffin’s Citadel Investment Group and Paul Marshall and Ian Wace’s Marshall Wace LLP.

Follow Alkermes Plc. (NASDAQ:ALKS)
Trade (NASDAQ:ALKS) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.